The Hoosier state has 17,093 industry jobs spread out among 69 companies, from Indianapolis-based drugmaker Eli Lilly and Co. to startups scattered around the state, but mostly in clusters near research universities.
The Indianapolis-based insurer says the treatments are “investigational”—or still under clinical study—but a California woman claims the electrical stimulation is FDA-approved and supported by numerous studies.
Taltz rang up sales of $1.3 billion last year, an increase of 46%, making it Lilly’s fastest-growing drug. An estimated 137,000 patients have been treated with Taltz worldwide since its launch four years ago.
The design of the long-anticipated project was originally set to be unveiled by the end of 2018, but has been delayed several times—most recently this spring, as the pandemic began to sweep across the United States.
Gov. Eric Holcomb lifted the ban effective Monday, with some caveats, such as making sure that hospitals keep enough personnel and personal protective equipment on hand for COVID-19 patients.
The two technologies are different, but the goal of both is to provide a result within 40 minutes. The researchers say they are working with manufacturers to develop the products, which they hope will retail for $5 or less.
Baricitinib, also known under the brand name Olumiant, is approved in more than 65 countries as a treatment for adults with moderately to severely active rheumatoid arthritis.
State officials declined to provide details on specifically how the hotel is being used—including whether it is a treatment site for homeless individuals—to protect patient privacy.
IUPUI said Monday it is cleaning and sanitizing University Tower to house health care workers, but no plans have been announced locally for temporary field hospitals.
Just like the pandemic that is sweeping the world, news about COVID-19 is developing almost too quickly to comprehend.